awmsg logo



triptorelin acetate (Decapeptyl®)


Reference No. 3076

Publication date:
13/07/2017


Appraisal information

triptorelin acetate (Decapeptyl®) 3 mg powder for suspension for injection


Company: Ipsen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 12/07/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, triptorelin acetate (Decapeptyl®) cannot be endorsed for use within NHS Wales as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
Statement of Advice (SOA)
Download